Journal of medical economics · 2026
Economic value of lost productivity attributable to premature cancer mortality and morbidity across Europe.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brandtmüller Agnes, Meiwald Anne, Toth Peter, Perera Chamath, Fox Aimee
Аннотация
BACKGROUND: Cancer imposes a substantial clinical and economic burden across Europe. This analysis estimated the lost productivity cost of the five cancer types with the highest premature mortality and five cancer types with the highest morbidity burden across 28 European countries in 2022.
METHODS: Data on cancer deaths, years of life lost (YLL), and years of life lived with disability (YLD) were sourced from the Institute for Health Metrics and Evaluation Global Burden of Disease database. Country- and sex-specific demographic and economic parameters were obtained. Years of productive life lost (YPLL) and present value of future lost productivity (PVFLP) were estimated for individuals dying before retirement, while the value of YLD (VYLD) quantified earnings lost due to cancer-related disability. Outcomes were adjusted for labor force participation and unemployment. Deterministic sensitivity analyses assessed the impact of variations in model inputs.
RESULTS: In 2022, tracheal, bronchus, and lung cancer, colon and rectum cancer, breast, pancreatic, and prostate cancers accounted for 899,581 deaths, 17,274,882 YLL, 896,510 YPLL, and €30,749,064,014 PVFLP across Europe. Tracheal, bronchus, and lung cancer contributed the largest share of mortality-related productivity losses with 37.2% of deaths and 43.7% of PVFLP. Breast cancer had the highest PVFLP per death (€49,411). For morbidity, breast, prostate, colon and rectum cancer, tracheal, bronchus, and lung cancer, and non-Hodgkin lymphoma resulted in 993,648 YLD, 210,400 productive YLD (PYLD), and €9,087,096,712 VYLD. Germany, France, and United Kingdom were the largest contributors to both mortality and morbidity burdens. Sensitivity analyses indicated that retirement age was the key driver of results.
CONCLUSION: Cancer continues to exert a considerable productivity burden across Europe with substantial variation between countries. These findings highlight the need for equitable cancer prevention, early diagnosis, and timely access to treatment to reduce both health and economic disparities across Europe.
METHODS: Data on cancer deaths, years of life lost (YLL), and years of life lived with disability (YLD) were sourced from the Institute for Health Metrics and Evaluation Global Burden of Disease database. Country- and sex-specific demographic and economic parameters were obtained. Years of productive life lost (YPLL) and present value of future lost productivity (PVFLP) were estimated for individuals dying before retirement, while the value of YLD (VYLD) quantified earnings lost due to cancer-related disability. Outcomes were adjusted for labor force participation and unemployment. Deterministic sensitivity analyses assessed the impact of variations in model inputs.
RESULTS: In 2022, tracheal, bronchus, and lung cancer, colon and rectum cancer, breast, pancreatic, and prostate cancers accounted for 899,581 deaths, 17,274,882 YLL, 896,510 YPLL, and €30,749,064,014 PVFLP across Europe. Tracheal, bronchus, and lung cancer contributed the largest share of mortality-related productivity losses with 37.2% of deaths and 43.7% of PVFLP. Breast cancer had the highest PVFLP per death (€49,411). For morbidity, breast, prostate, colon and rectum cancer, tracheal, bronchus, and lung cancer, and non-Hodgkin lymphoma resulted in 993,648 YLD, 210,400 productive YLD (PYLD), and €9,087,096,712 VYLD. Germany, France, and United Kingdom were the largest contributors to both mortality and morbidity burdens. Sensitivity analyses indicated that retirement age was the key driver of results.
CONCLUSION: Cancer continues to exert a considerable productivity burden across Europe with substantial variation between countries. These findings highlight the need for equitable cancer prevention, early diagnosis, and timely access to treatment to reduce both health and economic disparities across Europe.